The Supreme Court says it won’t wade in­to the phar­ma in­dus­try’s years­long le­gal bat­tle over Medicare drug price ne­go­ti­a­tions.

The jus­tices de­clinedto re­view mul­ti­ple...

An analy­sis launched by for­mer FDA lead­ers to look in­to claims of pe­di­atric deaths re­lat­ed to Covid-19 vac­cines was pub­lished by a Re­pub­li­can law­mak­er, months...

The FDA wants it off the mar­ket. Eu­ro­pean reg­u­la­tors are in­ves­ti­gat­ing da­ta-in­tegri­ty con­cerns. And now, a phar­ma com­pa­ny sell­ing the drug in Japan is warn­ing...

One of the key prod­ucts un­der­pin­ning As­traZeneca’s goal of hit­ting $80 bil­lion in rev­enue by 2030 has been ap­proved by the FDA, the drug­mak­er said...

An ex­per­i­men­tal an­ti­body-drug con­ju­gate from Mer­ck and Chi­na-based Kelun-Biotech suc­ceed­ed in a glob­al Phase 3 study for the first time, giv­ing Mer­ck a key pipeline...

Re­gen­eron Phar­ma­ceu­ti­cals’ LAG-3 in­hibitor called fi­an­limab has flunked a late-stage skin can­cer tri­al, mark­ing yet an­oth­er blow for the drug class.

The an­nounce­ment fol­lows a...